Answers are grounded in this paper and cite their sources.
Skull bone marrow supplies immune cells to CNS borders and receives signals through cerebrospinal fluid (CSF)-associated routes. This interface may contribute to Alzheimer’s disease (AD), but its anatomical connectivity is better established than its disease-specific functions. This narrative review examines five processes: sensing, hematopoiesis, trafficking, effector functions, and translation, with a focus on amyloid-associated evidence. We distinguish human observations, skull-specific experiments, and findings from systemic marrow or other CNS disorders. Human molecular profiling and PET studies support regional skull-marrow differences and disease-associated signals; they do not establish cell migration or causality. In AD mouse models, Aβ-associated IL-6 signaling promotes B-lineage responses, whereas osteoblast-dependent niche and channel remodeling alters myeloid trafficking. These findings support distinct, potentially interacting mechanisms rather than a single established pathway. Monocyte-derived macrophages are distinguished from embryonically derived resident populations, and skull-to-dura channels are separated from routes across the arachnoid. Local Aβ production, circulating exposure, and CSF-associated delivery remain competing explanations for marrow accumulation. Tau pathology and sex-dependent border immunity are relevant modifiers, but direct evidence linking them to skull-specific hematopoietic responses remains limited. We use “cranial hematopoietic reprogramming” as a working hypothesis and treat stage, lineage, genotype, and experimental context as separate determinants of outcome. Source-specific tracing and longitudinal, sex-stratified studies are needed before skull-marrow measurements or interventions can be assigned clinical value.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: